jitendra gohil people page on Anadi Algo News

Monday, April 6, 2026
DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|
People Landing|3 matching stories

jitendra gohil News, Mentions & Market Context

AI-analyzed market coverage and mentions for jitendra gohil, including related stories and trading context.

What Traders Do Next

jitendra gohil is more useful with a process around it.

Use these pages to understand the story first. Execution usually comes later, after the idea is filtered, tested, and sized correctly.

This is here if you want to go deeper, not as a push.Explore Anadi
Look for private banking stocks showing resilience or consolidation during market dips, with a bias towards accumulation.|Quick check: HDFCBANK neutral (+0.9% 1d), ICICIBANK bearish bias (+0.3% 1d).
et_companies18 days ago

India's nuclear plants generated 56,681 MU of power in 2024-25: Jitendra Singh

The Indian energy sector is undergoing a significant transition towards cleaner sources. Government emphasis on nuclear power provides a stable, long-term growth avenue amidst the broader power sector expansion.

Bullish+51.995%
5 facts
Look for entry points in established power generation and heavy engineering companies with exposure to nuclear projects, maintaining a medium to long-term bullish bias.|Quick check: RELIANCE bearish bias (-1.1% 1d), ONGC bullish bias (+1.7% 1d).
et_companies23 days ago

Kathua to become India’s antibiotic powerhouse with Rs 600 crore pharma facility

The Indian pharma sector is actively working to reduce its reliance on imported APIs, especially from China. This investment aligns with the government's 'Make in India' push and Production Linked Incentive (PLI) schemes for pharmaceuticals.

Look for opportunities in API-focused pharma companies, as this development signals continued government support and potential for domestic growth, with a bias towards long positions.|Quick check: AUROPHARMA bullish bias (overbought), DIVISLAB bearish bias (-3.5% 1d).